BR112012005208A2 - antiocorpos contra o receptor de glucagon e seu uso - Google Patents
antiocorpos contra o receptor de glucagon e seu usoInfo
- Publication number
- BR112012005208A2 BR112012005208A2 BR112012005208A BR112012005208A BR112012005208A2 BR 112012005208 A2 BR112012005208 A2 BR 112012005208A2 BR 112012005208 A BR112012005208 A BR 112012005208A BR 112012005208 A BR112012005208 A BR 112012005208A BR 112012005208 A2 BR112012005208 A2 BR 112012005208A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibodies against
- glucagon receptor
- glucagon
- receptor
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Obesity (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/KR2009/005084 WO2011030935A1 (en) | 2009-09-08 | 2009-09-08 | Antibodies against glucagon receptor and their use |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012005208A2 true BR112012005208A2 (pt) | 2016-11-22 |
Family
ID=43732588
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012005208A BR112012005208A2 (pt) | 2009-09-08 | 2009-09-08 | antiocorpos contra o receptor de glucagon e seu uso |
Country Status (11)
Country | Link |
---|---|
US (1) | US9102732B2 (pt) |
EP (2) | EP2475683A4 (pt) |
JP (1) | JP2013503626A (pt) |
KR (1) | KR20120056800A (pt) |
CN (1) | CN102482350B (pt) |
AU (1) | AU2009352373B2 (pt) |
BR (1) | BR112012005208A2 (pt) |
CA (1) | CA2772590C (pt) |
NZ (1) | NZ598670A (pt) |
RU (1) | RU2562110C2 (pt) |
WO (1) | WO2011030935A1 (pt) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE204879T1 (de) | 1991-12-24 | 2001-09-15 | Isis Pharmaceuticals Inc | Antisense oligonukleotide |
JO3756B1 (ar) * | 2010-11-23 | 2021-01-31 | Regeneron Pharma | اجسام مضادة بشرية لمستقبلات الجلوكاجون |
WO2013059531A1 (en) * | 2011-10-20 | 2013-04-25 | Genentech, Inc. | Anti-gcgr antibodies and uses thereof |
CA2911412A1 (en) * | 2013-05-07 | 2014-11-13 | Rinat Neuroscience Corp. | Anti-glucagon receptor antibodies and methods of use thereof |
RU2678421C2 (ru) | 2013-06-28 | 2019-01-28 | Экс-Боди, Инк. | Обнаружение антигена-мишени, фенотипический скрининг и его применение для идентификации специфичных эпитопов-мишеней клеток-мишеней |
EP3049811B1 (en) * | 2013-09-23 | 2020-09-09 | X-Body, Inc. | Methods and compositions for generation of binding agents against cell surface antigens |
SG11201701711VA (en) * | 2014-09-16 | 2017-04-27 | Regeneron Pharma | Anti-glucagon antibodies and uses thereof |
WO2017055966A1 (en) | 2015-10-01 | 2017-04-06 | Pfizer Inc. | Low viscosity antibody compositions |
CN107663239A (zh) * | 2016-12-28 | 2018-02-06 | 天津天锐生物科技有限公司 | 一种识别hla‑a2/nlvpmvatv的单域抗体 |
PE20191404A1 (es) | 2017-01-27 | 2019-10-04 | Ngm Biopharmaceuticals Inc | Proteinas de union al receptor de glucagon y metodos para usarlas |
CN110234352A (zh) * | 2017-01-31 | 2019-09-13 | Msm蛋白质技术公司 | 抗cxcr4抗体 |
CN110357959B (zh) * | 2018-04-10 | 2023-02-28 | 鸿运华宁(杭州)生物医药有限公司 | Gcgr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用 |
EP3829636A1 (en) | 2018-07-27 | 2021-06-09 | NGM Biopharmaceuticals, Inc. | Use of glucagon receptor antagonists with immunotherapeutic agent |
MX2021007444A (es) * | 2018-12-21 | 2021-08-05 | Jiangsu Hengrui Medicine Co | Proteina biespecifica. |
WO2024151051A1 (ko) * | 2023-01-09 | 2024-07-18 | 임정환 | 다량체를 형성하는 항원 결합 단편 및 이의 용도 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL178685B1 (pl) * | 1992-08-28 | 2000-06-30 | Zymogenetics Inc | Cząsteczka DNA kodująca receptor glukagonu lub peptyd receptora glukagonu, konstrukty DNA, komórka gospodarza zawierająca konstrukty DNA, peptyd receptora glukagonu i sposoby wytwarzania receptora glukagonu lub peptydu receptora glukagonu |
CL2007002668A1 (es) * | 2006-09-20 | 2008-05-09 | Amgen Inc | Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2. |
AR070844A1 (es) * | 2008-03-27 | 2010-05-05 | Lilly Co Eli | Fragmento fab o anticuerpo monoclonal humanizado que comprende el fragmento fab, y su uso para la manufactura de un medicamento antagonista del polipeptido del receptor de glucagon para el tratamiento o prevencion de diabetes de tipo 1 o 2 |
-
2009
- 2009-09-08 CN CN200980161348.6A patent/CN102482350B/zh not_active Expired - Fee Related
- 2009-09-08 EP EP20090849252 patent/EP2475683A4/en not_active Withdrawn
- 2009-09-08 RU RU2012113554/10A patent/RU2562110C2/ru not_active Application Discontinuation
- 2009-09-08 BR BR112012005208A patent/BR112012005208A2/pt not_active Application Discontinuation
- 2009-09-08 NZ NZ59867009A patent/NZ598670A/en not_active IP Right Cessation
- 2009-09-08 EP EP15193745.5A patent/EP3009453A1/en not_active Ceased
- 2009-09-08 KR KR20117028123A patent/KR20120056800A/ko not_active Application Discontinuation
- 2009-09-08 AU AU2009352373A patent/AU2009352373B2/en not_active Ceased
- 2009-09-08 JP JP2012527801A patent/JP2013503626A/ja not_active Withdrawn
- 2009-09-08 US US13/394,463 patent/US9102732B2/en active Active
- 2009-09-08 CA CA2772590A patent/CA2772590C/en active Active
- 2009-09-08 WO PCT/KR2009/005084 patent/WO2011030935A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
CN102482350B (zh) | 2015-08-05 |
US9102732B2 (en) | 2015-08-11 |
US20130149315A1 (en) | 2013-06-13 |
AU2009352373B2 (en) | 2016-05-12 |
CA2772590A1 (en) | 2011-03-17 |
RU2562110C2 (ru) | 2015-09-10 |
AU2009352373A1 (en) | 2012-04-05 |
WO2011030935A1 (en) | 2011-03-17 |
JP2013503626A (ja) | 2013-02-04 |
EP2475683A1 (en) | 2012-07-18 |
RU2012113554A (ru) | 2013-10-20 |
NZ598670A (en) | 2014-05-30 |
EP2475683A4 (en) | 2013-04-24 |
EP3009453A1 (en) | 2016-04-20 |
KR20120056800A (ko) | 2012-06-04 |
CA2772590C (en) | 2017-01-03 |
CN102482350A (zh) | 2012-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012005208A2 (pt) | antiocorpos contra o receptor de glucagon e seu uso | |
CY2021027I1 (el) | Σκευασματα αντισωματων anti-cd20 | |
BRPI0906478A2 (pt) | anticorpo anti-nr10 e uso do mesmo | |
BRPI1012533A2 (pt) | composto de piradazinona e uso do mesmo | |
ECSP12011965A (es) | Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico | |
BR112012002349A2 (pt) | composto,e, uso do mesmo | |
BRPI1007494A2 (pt) | composto e uso do mesmo | |
BRPI1012321A2 (pt) | anticorpos anti-vegf e seus usos | |
BRPI0917535A2 (pt) | uso de insulina de ação ultra rápida | |
BRPI0821668A2 (pt) | Uso | |
BRPI0821110A2 (pt) | Anticorpo anti nr-10 e uso do mesmo | |
BR112012013148A2 (pt) | formulação farmacêutica e uso | |
IL218740A0 (en) | New maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody | |
BRPI1010621A2 (pt) | derivado de imidazoquinolinonas, sua composição farmacêutica e seu uso | |
BRPI0906498A2 (pt) | Anticorpo ron e seus usos | |
BRPI0813263A2 (pt) | Oxazolidinonas substituídas e seu uso | |
BRPI0816372A2 (pt) | Ácidos 6-fenilnicotínicos substituídos e seu uso | |
BR112012003066A2 (pt) | uso de um anticorpo anti-cd20 defucosilado e composição compreendendo um anticorpo anti-cd20 defucosilado | |
BRPI0814231A2 (pt) | Derivados de pleuromutilina e seu uso como antimicrobianos | |
BR112012002572A2 (pt) | co- polímero catiônico ou anfotérico e seu uso | |
BRPI1011036A2 (pt) | uso | |
BRPI1005804A2 (pt) | unidade redutora de material, uso de unidade redutora de material, e fixador de conteúdo de material reduzido | |
BR112013014779A2 (pt) | composição de filtro solar e uso | |
BRPI0810498A2 (pt) | Composto amida e seu uso | |
BRPI1011417A2 (pt) | uso de malonatos de benzilideno, preparação cosmética,e, malonatos de benzilideno. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |